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The recent publication of several large well-
conducted trials on hydroxyethyl starch (HES) has 
led to a re-examination of evidence for colloids in 
medicine. A Cochrane review[1] showed no mortality 
advantage from HES, albumin, modified gelatins or 
dextran when compared with crystalloids. A 2011 review of HES[2] 
raised concerns of increased harm, particularly with older HES 
formulations, and this concern was reiterated in a 2013 review.[3] In 
a recent editorial[4] it was suggested that the accrued evidence now 
allows us to declare that starches have reached the ‘end of the road’ in 
the care of critically ill patients with sepsis.
In such patients the baseline mortality rate can be as high as 
40%. [5] Even assuming half that (20%), a relative risk of 1.09 gives an 
absolute mortality increase of 1.8%, or one extra death for every 56 
high-risk patients prescribed HES as used in the underlying trials. 
The South African (SA) public sector spent R45 million on HES in 
2011 (pharmaceutical directorate, personal communication). If HES 
was used in a similar way to that in the sepsis trials, this might mean 
several hundred excess deaths annually in this country alone.
The new trials
The CHEST study[6] compared 90-day mortality in 7 000 patients 
admitted to intensive care units (ICUs) and resuscitated with either 
6% HES 130/0.4 or saline. The two groups had similar mortality 
rates, but more patients in the HES group required renal replacement 
therapy (7.0% v. 5.8%; relative risk (RR) 1.21, 95% confidence interval 
(CI) 1.00 - 1.45). Patients in the 6S study[5] had severe sepsis and were 
given 6% HES 130/0.42 or Ringer’s acetate. Mortality at 90 days in the 
398 patients in the HES group was 51%, while it was 43% in the 400 
assigned to Ringer’s acetate (RR 1.17, 95% CI 1.01 - 1.36). At 90 days, 
more patients in the HES group needed renal replacement therapy 
(22% v. 16%; RR 1.35, 95% CI 1.01 - 1.80).
The same pattern was seen in the 196-patient CRYSTMAS study,[7] 
which was only powered to detect a difference in volumes infused 
between 6% HES 130/0.4 and saline in patients with sepsis. The 
product manufacturer was involved in the design, analysis and write-
up of the study. The 90-day mortality was non-significantly higher 
in the HES group (40% v. 33% using intention to treat data; RR 1.2, 
95% CI 0.83 - 1.74).
VISEP[8] (2008) compared the older 10% HES 200/0.5 with Ringer’s 
lactate in 537 patients with severe sepsis. Total HES volumes infused 
were high, with a median cumulative volume of 70 ml/kg, and the 
dose limit of 20 ml/kg/day was exceeded by more than 10% on at least 
one day in more than 38% of patients. The trial was stopped early 
because of increased renal failure and a trend to increased mortality 
in the HES group. Mortality at 90 days was 41% in the HES group 
and 33.9% in the control group (RR 1.21, 95% CI 0.97 - 1.51). Renal 
replacement therapy was required in 31% of the HES group and in 
18.8% of controls (RR 1.66, 95% CI 1.22 - 2.25).
Further interesting studies await publication. The blinded 
240-patient Basel study for the evaluation of starch infusion for 
septic patients (BaSES[9]) was completed in May 2011. The unblinded 
3 000-patient CRISTAL trial[10] compared ‘any colloid’ with crystalloid. 
The latter trial was reported (International Symposium on Intensive 
Care and Emergency Medicine 2013) to show a statistically significant 
overall survival benefit from early colloid use, but the details await 
full publication and careful HES subgroup analysis.
New systematic reviews
There have been several recent high-quality systematic reviews 
(Table 1). The Cochrane review on colloids was updated in 2013.[1] 
The RR of death in 15 trials of HES was 1.10 (95% CI 1.02 - 1.19), 
and that in the Gattas review[11] (third-generation HES products) 
was 1.08 (95% CI 0.97 - 1.21). Most recently, Zarychanski et al. 
performed a high-quality systematic review of all HES products. [3] 
The mortality RR was 1.09 (1.02 - 1.17) after excluding seven early 
trials by Boldt et al., whose research corpus must be regarded 
with caution after multiple retractions.[12] The Haase review,[13] 
looking only at a highly defined subset of starch trials (high-
quality trials, third-generation HES, sepsis), found a very similar 
RR of 1.11 but with an expected wider CI (1.00 - 1.23). ‘Multiple-
look’ meta-analyses increase the risk of false-positive results, 
which was addressed in this review using trial sequential analysis 
(wider 95% CI 0.95 - 1.29). None of the other patient-relevant 
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clinical endpoints, such as length of ICU stay, use of mechanical 
ventilation or presence of major bleeding, showed a statistically 
significant advantage of HES over crystalloids.
Renal harm
Both the Gattas[11] and Zarychanski[3] reviews found convincing 
evidence of renal harm. In Gattas et al.’s review, there was a 27% 
relative increase in the need for renal replacement therapy in patients 
given HES compared with crystalloid (RR 1.27, 95% CI 1.10 - 1.46). 
The equivalent RR in the Zarychanski review was 1.32 (95% CI 1.15 
- 1.50) where the control intervention was not always crystalloid.
Assessing the potential for harm
Formal assessment of harm is complex, and may be unfamiliar to 
clinicians without expertise in pharmaco-epidemiology. Convincing 
safety signals usually require large numbers in the numerator, and 
registration trials are underpowered for this. Patient numbers several 
times higher than those used in efficacy trials are required. Accrual 
of harms may not proceed at the same rate as benefits, so acute 
resuscitation trials with short-term endpoints will not detect harms 
taking weeks to accrue. An appropriate comparator is important – 
pooling trials where some control groups were given other colloids 
rather than crystalloids dilutes harm signals.
The 0.05 type I error rate used to measure the certainty of an effect 
is purported to have originated with Fischer[14] and was adopted by 
the Food and Drug Administration (FDA)[15] and other medicines 
regulators. It makes sense to minimise the probability of a false-positive 
statement when determining efficacy. However, do we need to be 95% 
sure of danger before avoiding a course of action?[16] Table 2 illustrates 
the effect of changing type 1 error rates on statements of certainty.
Unlike the albumin controversy, where an earlier Cochrane 
review[17] raised concerns about harm that were not confirmed in a 
subsequent large trial (SAFE[18]), the current HES harm signal comes 
from information on more than 10 000 patients and is robust.
Scoring reviews versus keeping score 
of the number of reviews
Manufacturers react appropriately to safety concerns by 
commissioning reviews. Guidelines on assessing the quality of a 
systematic review exist.[19] High-quality reviews are reliable if the 
underlying trials are unbiased, and if adequate patient numbers 
have accrued. A ‘review of reviews’ on HES raises some concerns. [20] 
The authors identified 165 reviews published between 1976 and 
2010, of which 7% contained a meta-analysis. Of the higher-quality 
reviews, 83% were not supportive of HES versus 20% of the lower-
quality reviews. Of 124 positive reviews, 70 were written by only 14 
experts, and 10 of these authors had identifiable potential conflicts of 
interest. An unsuspecting reader is more likely to encounter multiple 
low-quality positive reviews than the few high-quality ones. Simple 
repetition does not imply truth.
Identifying industry influence
It is helpful to identify reviews at risk of bias. Clues include finding 
authors with clear affiliations to HES manufacturers, reviews listing 
Table 1. Hydroxyethyl starch reviews 
Mortality Renal harm*
Author Date Indication HES type Bias risk RR (95% CI) 
No. of 
studies (total 




Hartog et al.[2] 2011 80% elective 
surgery
130/0.4 Insufficient data 56
Perel et al. 
(Cochrane)[1]
2013 ‘Critically ill 
patients’
All Low 1.10 (1.02 - 1.19) 15 (9 147)




Low 1.08 (0.97 - 1.21) 10 (8 367) 1.27 (1.10 - 1.46) 6 (8 141) 
Zarychanski et al.[3] 2013 ‘Critically ill 
patients’
All Moderate 1.09 (1.02 - 1.17) 28 (10 290) 1.32 (1.15 - 1.50) 10 (9 258) 




1.11 (1.00 - 1.23) 4 (3 016) 1.36 (1.08 - 1.72) 5 (1 311)
RR = relative risk; CI = confidence interval.
*Renal harm measured as need for renal replacement therapy.
Table 2. Sensitivity analysis* of differences in type I error rate for a pooled effect size (mortality) from the three major trials 
(VISEP,[8] CHEST,[6] 6S[5])
Confidence interval Relative risk 1.10 Risk difference 0.021 Statistically significant
99% 0.990 - 1.225 -0.002 - 0.044 No
95% 1.015 - 1.194 0.003 - 0.038 Yes
90% 1.029 - 1.178 0.006 - 0.036 Yes
50% 1.071 - 1.132 0.015 - 0.027 Yes
33% 1.082 - 1.121 0.017 - 0.025 Yes
If VISEP, which contributes only 6.7% of the weight of the combined three trials, is omitted, for the remaining two trials the relative risk of death changes to 1.088, with a 95% CI from 0.997 to 
1.187, and a 90% CI from 1.011 to 1.170.
*Mantel-Haenszel, fixed-effect meta-analysis.
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a manufacturer as sponsor or originator of a review, and reviews 
looking at endpoints where the focus is on physiological variables 
or other short-term surrogate markers rather than patient-relevant 
clinical measures. Missing features often include a clearly defined 
trial search strategy, and a table listing inclusions and exclusions, and 
the reasons for these. Lack of power to detect harm even after study 
pooling may be underemphasised. Measure of internal validity (trial 
quality scores) may be absent, and control groups inappropriate. 
Pooling methods may be unusual or use methods that do not take 
account of differences in baseline prevalence and trial size.[21] The 
introduction and discussion sections may contain non-scientific 
‘emotive’ words and product trade names.
For example, a 2013 industry-associated review[22] of 17 studies 
of HES in surgical patients found ‘no evidence of renal dysfunction’. 
Only 6 of these studies (a total of 437 patients) had a crystalloid 
comparator, trial quality was not formally reported, and there was 
evidence of heterogeneity.
Conclusion
Imagine another decade of HES use following current practice. If 
industry-associated opinion leaders are right, our patients would 
be unscathed. However, if the systematic reviews are correct, we 
would have ignored powerful signals of harm, and continued to 
expose our patients to a product that may increase mortality in 
sepsis, and may increase the need for dialysis in resuscitation. With 
these caveats, and in the absence of adequately powered studies to 
confirm safety in other situations, it is difficult to justify ongoing 
use of these products.
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